Limits...
Conditional TGF-β1 treatment increases stem cell-like cell population in myoblasts.

Mu X, Li Y - J. Cell. Mol. Med. (2011)

Bottom Line: The limitation in successfully acquiring large populations of stem cell has impeded their application.In addition to the C2C12 myoblasts, similar effects of TGF-β(1) were also observed in the primary myoblasts of mice.Our results suggest that TGF-β(1) is effective as a molecular trigger for the dedifferentiation of skeletal muscle myoblasts and could be used to generate a large pool of progenitor cells that collectively behave as multipotent stem cell-like cells for regenerative medicine applications.

View Article: PubMed Central - PubMed

Affiliation: The Laboratory of Molecular Pathology, Stem Cell Research Center, Children's Hospital of UPMC, Pittsburgh, PA, USA.

Show MeSH

Related in: MedlinePlus

S-phase re-entry of proliferation-arrested C2C12 myoblasts by TGF-β1 treatment. C2C12 myoblasts pre-treated with hrTGF-β1 (0.1, 0.5 and 2 ng/ml, 3 hrs) showed increased BrdU incorporation after incubation with BrdU. BrdU: green; DAPI: blue (A–E). PI staining/flow cytometry analysis shows that more cells were present in the S-phase in the cells pre-treated with TGF-β1 (0.5 ng/ml, 3 hrs) (F). ‘*’ indicates the value being significantly different with the control cells (0 ng/ml of TGF-β1).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3008543&req=5

fig02: S-phase re-entry of proliferation-arrested C2C12 myoblasts by TGF-β1 treatment. C2C12 myoblasts pre-treated with hrTGF-β1 (0.1, 0.5 and 2 ng/ml, 3 hrs) showed increased BrdU incorporation after incubation with BrdU. BrdU: green; DAPI: blue (A–E). PI staining/flow cytometry analysis shows that more cells were present in the S-phase in the cells pre-treated with TGF-β1 (0.5 ng/ml, 3 hrs) (F). ‘*’ indicates the value being significantly different with the control cells (0 ng/ml of TGF-β1).

Mentions: C2C12 myoblasts were cultured in serum-free DMEM for 24 hrs to allow for proliferation arrest and differentiation. Cells were then transiently treated with hrTGF-β1 (0, 0.1, 0.5 and 2.0 ng/ml) before being cultured with BrdU in the growth medium for 12 hrs. The ratio of cells with newly synthesized DNA (BrdU+) can indicate if and what dosage of TGF-β1 treatment can induce S-phase re-entry of proliferation-arrested C2C12 myoblasts. Results showed that TGF-β1 treatment, especially at 0.5 ng/ml, resulted in a greater number of BrdU+ cells than the control non-treated groups (Fig. 2A–E), indicating that S-phase re-entry occurred after treatment. In another experiment, proliferation-arrested C2C12 myoblasts were treated with hrTGF-β1 (0.5 ng/ml) and then cultured for another 5 hrs in growth medium before being harvested for PI staining. Compared to control groups, more cells were detected in S-phase (47.13%versus 29.33%) in the TGF-β1 treated groups (Fig. 2F), indicating the S-phase re-entry of some cells after TGF-β1 treatment. The promoted cell cycle re-entry by TGF-β1 stimulation may also indicate improved capabilities of self-renewal and long-term proliferation, which are similar to the characteristics of muscle stem cells [42].


Conditional TGF-β1 treatment increases stem cell-like cell population in myoblasts.

Mu X, Li Y - J. Cell. Mol. Med. (2011)

S-phase re-entry of proliferation-arrested C2C12 myoblasts by TGF-β1 treatment. C2C12 myoblasts pre-treated with hrTGF-β1 (0.1, 0.5 and 2 ng/ml, 3 hrs) showed increased BrdU incorporation after incubation with BrdU. BrdU: green; DAPI: blue (A–E). PI staining/flow cytometry analysis shows that more cells were present in the S-phase in the cells pre-treated with TGF-β1 (0.5 ng/ml, 3 hrs) (F). ‘*’ indicates the value being significantly different with the control cells (0 ng/ml of TGF-β1).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3008543&req=5

fig02: S-phase re-entry of proliferation-arrested C2C12 myoblasts by TGF-β1 treatment. C2C12 myoblasts pre-treated with hrTGF-β1 (0.1, 0.5 and 2 ng/ml, 3 hrs) showed increased BrdU incorporation after incubation with BrdU. BrdU: green; DAPI: blue (A–E). PI staining/flow cytometry analysis shows that more cells were present in the S-phase in the cells pre-treated with TGF-β1 (0.5 ng/ml, 3 hrs) (F). ‘*’ indicates the value being significantly different with the control cells (0 ng/ml of TGF-β1).
Mentions: C2C12 myoblasts were cultured in serum-free DMEM for 24 hrs to allow for proliferation arrest and differentiation. Cells were then transiently treated with hrTGF-β1 (0, 0.1, 0.5 and 2.0 ng/ml) before being cultured with BrdU in the growth medium for 12 hrs. The ratio of cells with newly synthesized DNA (BrdU+) can indicate if and what dosage of TGF-β1 treatment can induce S-phase re-entry of proliferation-arrested C2C12 myoblasts. Results showed that TGF-β1 treatment, especially at 0.5 ng/ml, resulted in a greater number of BrdU+ cells than the control non-treated groups (Fig. 2A–E), indicating that S-phase re-entry occurred after treatment. In another experiment, proliferation-arrested C2C12 myoblasts were treated with hrTGF-β1 (0.5 ng/ml) and then cultured for another 5 hrs in growth medium before being harvested for PI staining. Compared to control groups, more cells were detected in S-phase (47.13%versus 29.33%) in the TGF-β1 treated groups (Fig. 2F), indicating the S-phase re-entry of some cells after TGF-β1 treatment. The promoted cell cycle re-entry by TGF-β1 stimulation may also indicate improved capabilities of self-renewal and long-term proliferation, which are similar to the characteristics of muscle stem cells [42].

Bottom Line: The limitation in successfully acquiring large populations of stem cell has impeded their application.In addition to the C2C12 myoblasts, similar effects of TGF-β(1) were also observed in the primary myoblasts of mice.Our results suggest that TGF-β(1) is effective as a molecular trigger for the dedifferentiation of skeletal muscle myoblasts and could be used to generate a large pool of progenitor cells that collectively behave as multipotent stem cell-like cells for regenerative medicine applications.

View Article: PubMed Central - PubMed

Affiliation: The Laboratory of Molecular Pathology, Stem Cell Research Center, Children's Hospital of UPMC, Pittsburgh, PA, USA.

Show MeSH
Related in: MedlinePlus